The integrin ␣ IIb ␤ 3 mediates tyrosine phosphorylation of a 105-kDa protein (pp105) in activated platelets. We have partially purified a 105-kDa tyrosine-phosphorylated protein from platelets stimulated with phorbol 12-myristate 13-acetate and obtained the sequence of an internal 12-mer peptide derived from this protein. The sequence was identical to human ␣-actinin sequences deposited in the Swiss Protein Database. ␣-Actinin, a 105-kDa protein in platelets, was subsequently purified from activated platelets by four sequential chromatographic steps. Fractions were analyzed by Western blotting and probed with ␣-actinin and anti-phosphotyrosine antibodies. The distribution of ␣-actinin and pp105 overlapped throughout the purification. Furthermore, in the course of this purification, a 105-kDa tyrosine-phosphorylated protein was only detected in fractions that contained ␣-actinin. The purified ␣-actinin protein was immunoprecipitated with antibodies to phosphotyrosine in the absence but not in the presence of phenyl phosphate. ␣-Actinin resolved by two-dimensional gel electrophoresis of activated platelet lysates was recognized by the antibodies to phosphotyrosine, whereas pretreatment of the platelets with bisindolylmaleimide, a protein kinase C inhibitor that prevents tyrosine phosphorylation of pp105, inhibited the reactivity of the antibodies to phosphotyrosine with ␣-actinin. Taken together, these data demonstrate that a fraction of ␣-actinin is tyrosine-phosphorylated in activated platelets.
The integrin ␣ IIb ␤ 3 mediates tyrosine phosphorylation of a 105-kDa protein (pp105) in activated platelets. We have partially purified a 105-kDa tyrosine-phosphorylated protein from platelets stimulated with phorbol 12-myristate 13-acetate and obtained the sequence of an internal 12-mer peptide derived from this protein. The sequence was identical to human ␣-actinin sequences deposited in the Swiss Protein Database. ␣-Actinin, a 105-kDa protein in platelets, was subsequently purified from activated platelets by four sequential chromatographic steps. Fractions were analyzed by Western blotting and probed with ␣-actinin and anti-phosphotyrosine antibodies. The distribution of ␣-actinin and pp105 overlapped throughout the purification. Furthermore, in the course of this purification, a 105-kDa tyrosine-phosphorylated protein was only detected in fractions that contained ␣-actinin. The purified ␣-actinin protein was immunoprecipitated with antibodies to phosphotyrosine in the absence but not in the presence of phenyl phosphate. ␣-Actinin resolved by two-dimensional gel electrophoresis of activated platelet lysates was recognized by the antibodies to phosphotyrosine, whereas pretreatment of the platelets with bisindolylmaleimide, a protein kinase C inhibitor that prevents tyrosine phosphorylation of pp105, inhibited the reactivity of the antibodies to phosphotyrosine with ␣-actinin. Taken together, these data demonstrate that a fraction of ␣-actinin is tyrosine-phosphorylated in activated platelets.
Tyrosine phosphorylation of protein substrates is central to all cellular processes that are regulated by the integrin family of extracellular matrix receptors (1) including cell shape change, migration, growth, and survival (for recent reviews see Refs. [2] [3] [4] [5] [6] . The array of responses regulated by integrins is greatly simplified in platelets that are enucleated, terminally differentiated cells. Platelets, therefore, provide a useful model system to study integrin-mediated protein tyrosine phosphorylation events that are closely linked to cell shape change and the underlying cytoskeleton organization.
A rapid increase in protein tyrosine phosphorylation is detected within seconds to minutes of platelet activation by soluble agonists such as thrombin or phorbol 12-myristate 13-acetate (PMA) 1 (7, 8) . Platelet adhesion to immobilized matrix proteins such as fibrinogen triggers similar tyrosine phosphorylation events (9) . Included in the first group of proteins that become tyrosine-phosphorylated are the non-receptor tyrosine kinases pp72syk (10) and RFTK/PYK (11), the guanine nucleotide exchange factor Vav (12) , and the mitogen-activated protein (MAP) kinase family members extracellular signal-regulated kinase 2 (ERK2) and p38 (13, 14) . In platelets stimulated by thrombin, PMA, or adhesion to fibrinogen, a second wave of protein tyrosine phosphorylation that is strictly dependent on both ligand binding to the ␣ IIb ␤ 3 integrin receptor and the cytoskeleton organization is observed (7) . As such, tyrosine phosphorylation of this subset of protein substrates is effectively blocked by either ␣ IIb ␤ 3 receptor antagonists or cytochalasin D, an inhibitor of actin filament assembly. The protease calpain (15) , the phosphatase SHIP (16) , and the non-receptor protein tyrosine kinases Tec (17) and pp125 FAK (18, 19) are among the proteins that become phosphorylated at this stage.
Tyrosine phosphorylation of two additional proteins of 101 and 105 kDa (pp101 and pp105) is also detected in platelets that aggregate following stimulation with an agonist such as PMA and in platelets adherent and spread on fibrinogen (9, 20 -22) . Both platelet aggregation and adhesion to fibrinogen are mediated by the integrin ␣ IIb ␤ 3 . Platelet spreading on fibrinogen and tyrosine phosphorylation of pp125 FAK , pp101, and pp105 are inhibited by protein kinase C, PI3-kinase, and phospholipase A 2 enzyme(s) (21, 23, 24) . However, in platelets adherent to IgG, an Fc␥RIIA receptor-dependent interaction, protein kinase C (23-25) inhibitors but not PI3-kinase or phospholipase A 2 enzyme inhibitors affect the phosphorylation of these proteins, demonstrating that multiple signaling mechanisms converge to govern the phosphorylation of these proteins.
The goal of this study was to isolate and characterize pp105. To this end, a 105-kDa tyrosine-phosphorylated protein was partially purified from platelets stimulated with PMA and subjected to microsequencing. The sequence of an internal 12-mer peptide derived from the partially purified protein was identical to human ␣-actinin sequences deposited in the Swiss Protein Database. Consistent with the possibility that ␣-actinin is tyrosine-phosphorylated in platelets, ␣-actinin tyrosine phosphorylation was recently reported in other experimental systems (26, 27) . To further confirm the identity of pp105 as ␣-actinin, ␣-actinin was purified from activated platelets by four sequential chromatographic steps. The purified protein was recognized and immunoprecipitated by antibodies to phosphotyrosine. In addition, the antibodies to phosphotyrosine recognized ␣-actinin resolved by two-dimensional gel electrophoresis of activated platelet lysates. Collectively, these data demonstrate that a fraction of ␣-actinin is tyrosine phosphorylated in activated platelets.
MATERIALS AND METHODS
Platelet Isolation-Human platelets were isolated by gel filtration from freshly drawn blood anticoagulated with 0.15 volumes of NIH formula A acid-citrate-dextrose solution supplemented with 1 M prostaglandin E 1 and 1 unit/ml apyrase as described previously (9) . Platelet concentration was adjusted to 2-5 ϫ 10 8 platelets/ml in an incubation buffer containing 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl 2 , 5.6 mM glucose, 1 mg/ml bovine serum albumin, 3.3 mM NaH 2 PO 4 , and 20 mM HEPES, pH 7.4. Platelet adhesion to fibrinogen (100 g/ml) was studied in electrically untreated polystyrene plates pre-coated with the specific protein and blocked with bovine serum albumin as described previously (9) .
Partial Purification of a 105-kDa Tyrosine-phosphorylated Protein(s)-To purify large amounts of protein, platelets were isolated as described above from 1 to 2 units of outdated platelets that were purchased from the New Jersey Blood Bank. The isolated platelets were activated for 20 min with 10 nM PMA. Platelet aggregates were collected by 5 min of centrifugation at 800 ϫ g. The platelet pellet from each unit was resuspended in 20 ml of buffer containing 0.02% Triton X-100, 1 mM EGTA, 50 mM Tris-HCl, pH 8.0, 1 mM Na 3 VO 4 , and 1 mM phenylmethylsulfonyl fluoride (lysis buffer) and lysed by sonication. All subsequent steps were carried out at 4°C. Insoluble material was removed by 15 min of centrifugation at 15,000 ϫ g. Ammonium sulfate was added sequentially to the supernatant to yield final concentrations of 10, 20, 30, and 40%. At each step the solution was mixed for at least 45 min prior to a 15-min centrifugation at 15,000 ϫ g. Proteins precipitated in the presence of 10, 20, 30, and 40% ammonium sulfate were reconstituted in lysis buffer and dialyzed extensively. All fractions were subsequently centrifuged for 15 min at 15,000 ϫ g. Duplicate samples from each fraction were analyzed by Western blots probed with the mAb to phosphotyrosine, 4G10, and by silver staining of gels. Most, if not all tyrosine-phosphorylated proteins precipitated in the presence of less than 40% ammonium sulfate. The proteins re-solubilized and dialyzed following precipitation with 30% and 40% ammonium sulfate were combined and applied to a DEAE-Sepharose ion exchange column (1.0 ϫ 4 cm) pre-equilibrated with lysis buffer. Proteins retained on the column were eluted with a step gradient of 0.2, 0.4, 0.6, 0.8, and 1 M NaCl prepared in lysis buffer (two column volumes were used for each NaCl concentration). Proteins eluted off the DEAE column were dialyzed, concentrated, and analyzed by Western blots probed with mAb 4G10. Subsequently, proteins contained in the fractions eluted with 0.8 and 1 M NaCl were combined and Western-blotted onto an Immobilon polyvinylidene difluoride membrane. The membrane was stained with India ink, and the 105-kDa region was excised. Protein digestion with endoproteinase Lys-C, HPLC fractionation, and internal peptide sequencing were carried out by the microsequencing facility at the Rockefeller University (28) .
␣-Actinin Purification-␣-actinin was purified from two units of outdated platelets. Platelets were isolated by gel filtration and stimulated for 20 min with 50 nM PMA. A purification flow chart is shown in Fig.  3 . Platelet aggregates were collected by 5 min of centrifugation at 800 ϫ g. The resulting pellet was resuspended in 5 ml of buffer containing 50 mM Tris-HCl, pH 9.0, 200 mM NaCl, 10 mM CaCl 2 , 1 mM Na 3 VO 4 and 1 mM phenylmethylsulfonyl fluoride (buffer 1). The activated platelets were lysed by sonication. The lysate was cleared by 20 min of centrifugation at 17,000 ϫ g. The resulting supernatant was resolved by gel filtration on a Sephacryl 300-HR column (1.6 ϫ 70 cm) at a constant flow of 0.32 ml/min in buffer 1. Fractions containing ␣-actinin were identified by Western blots and probing with mAb 4G10 and an ␣-actinin antiserum and were combined. KCl was added to the protein solution to reach 0.6 M. The solution was vigorously vortexed and dialysis-concentrated against buffer containing 50 mM Tris-HCl, pH 9.0, 0.6 M KCl, 10 mM CaCl 2 , and 1 mM Na 3 VO 4 (buffer 2) utilizing a concentrator apparatus (Schleicher & Schuell) equipped with a collodion bag with a molecular mass cut-off of 75 kDa. The volume was reduced to 5 ml or less. The sample was centrifuged for 60 min at 100,000 ϫ g (20°C; SW Ti55 Beckman rotor). The supernatant was further dialysis-concentrated to 2 ml and then subjected to gel filtration on a Sephacryl 300-HR column (1.6 ϫ 70 cm) pre-equilibrated with buffer 2 at a constant flow of 0.32 ml/min. Fractions containing ␣-actinin were identified by Western blots, as described above, and combined. The protein solution was dialysis-concentrated down to 2 ml against buffer containing 50 mM Tris-HCl, pH 7.6, 10 mM CaCl 2 , 1 mM Na 3 VO 4 (buffer 3). This sample was passed through a CM-Sepharose column (1.2 ϫ 14 cm) at a flow of 1 ml/min. ␣-Actinin was not retained on this column. ␣-Actinin-containing fractions were pooled and loaded onto a DEAE-Sepharose column (1.2 ϫ 14 cm) pre-equilibrated with buffer 3.
The column was washed with 30 ml of the loading buffer, and proteins were eluted off the column with a linear increase in NaCl concentration from 0 -0.5 M in 40 ml of buffer 3. Fractions containing ␣-actinin were identified by Western blots and combined. All chromatographic analyzes were performed at room temperature.
Western Blots and Immunoprecipitation Analysis-Tyrosine-phosphorylated proteins were detected in most experiments using mAb 4G10 (Upstate Biotechnology). In some experiments, mAb PY-20 (Transduction Laboratories) or mAb PY-99 (Santa Cruz Biotechnology) were used yielding indistinguishable results. Two ␣-actinin antiserums were used. One antiserum was purchased from Sigma (A-2543). This antiserum was used to generate the data shown in Fig. 1 . A second antiserum was generated by us by immunizing rabbits with a 14-mer peptide derived from residues 25-38 of human ␣-actinin (Swiss Protein Database accession number P12814, aac1_human). Attempts to precipitate ␣-actinin with either ␣-actinin antiserum were unsuccessful. Antibody reactivity was detected using horseradish peroxidase-conjugated secondary antibodies (Bio-Rad). Phosphotyrosine-containing proteins and ␣-actinin were visualized by chemiluminescent detection with ECL (Amersham Pharmacia Biotech). To immunoprecipitate tyrosine-phosphorylated proteins, samples were pre-cleared for 1 h with 20 l of protein A/G agarose beads (Santa Cruz Biotechnology) followed by an overnight incubation with mAb PY-20 (4 g/sample) in the presence or absence of 50 M phenyl phosphate. Antibody-antigen complexes were immunoprecipitated with 20 l of protein A/G-agarose beads, eluted with sample buffer, and analyzed by SDS-PAGE.
Protein Dephosphorylation-Fibrinogen-adherent platelets were lysed in buffer containing 20 mM Tris-HCl, pH 8.0, 0.02% Triton X-100, 1 mM EGTA, 1 mM Na 3 VO 4 , and 1 mM phenylmethylsulfonyl fluoride. Lysates containing 60 g protein/lane were resolved by gel electrophoresis and transferred onto nitrocellulose. The membrane was blocked from 2 h to overnight with 2% albumin (Fraction V, ICN) in buffer containing 50 mM Tris, pH 7.5, 150 mM NaCl, and 0.03% sodium azide. The membrane was separated into strips each representing one lane of the gel. The strips were submerged in solution containing 20 mM Tris-HCl, pH 7.2, 150 mM NaCl, 0.1% mercaptoethanol, and 1 mg/ml bovine serum albumin with or without 25 milliunits/ml of protein tyrosine phosphatase (PTPase), a recombinant 34-kDa fragment from Yersinia enterocolitica (from Roche Molecular Biochemicals). Dephosphorylation was carried out at room temperature. At times 0 and 60 min, one strip from each group was removed, rinsed in water, and placed in 50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.02% Nonidet P-40, 1 mg/ml bovine serum albumin, and 1 mM Na 3 VO 4 overnight. The strips were probed with mAb 4G10 and the antiserum to ␣-actinin.
Two-dimensional Gel Electrophoresis-Two approaches were used for protein separation in the first (pI) dimension. The first approach involved lysis of fibrinogen adherent platelets or PMA-stimulated platelets in boiling 2% SDS in 66 mM Tris, pH 8.0. In some experiments, platelets were treated for 1 h with 12 M bisindolylmaleimide, a protein kinase C inhibitor, (29) to prevent platelet spreading and pp105 tyrosine phosphorylation (21) . Isoelectric focusing of samples containing 50 g of protein was carried out in a glass tube using 2% pH 4 -8 ampholines (BDH from Hoefer Scientific Instruments, as described in Ref. 30 ). Second-dimension SDS-PAGE was carried out on 8% acrylamide gels. The two-dimensional gel analysis was performed by Kendrick Laboratories Inc. (Madison, WI).
The second two-dimensional gel analysis performed by us entailed the use of polyacrylamide gels that are pre-cast on plastic support film and contain an immobilized pH gradient of 3-10 (Immobiline DryStrips, Amersham Pharmacia Biotech). Unstimulated, fibrinogen-adherent, and PMA-stimulated platelets were lysed in 9 M urea, 2% Triton X-100, and 10 mM dithiothreitol. 50 -100 g of protein were loaded onto the Immobiline DryStrips. First-dimension electrophoresis was performed utilizing the Multiphor II apparatus (Amersham Pharmacia Biotech) following the procedure described by the manufacturer. Second-dimension SDS-PAGE was carried out on 7% acrylamide gels.
RESULTS

Partial Purification of a 105-kDa Tyrosine-phosphorylated
Protein from Activated Platelets-Platelet activation with soluble agonists such as PMA as well as platelet adhesion to immobilized matrix proteins such as fibrinogen (9, 31, 32) triggers the induction of tyrosine phosphorylation of proteins that migrate with an apparent molecular mass of 101-105 kDa (pp101 and pp105) (Fig. 1A) . To begin to characterize these proteins, we set out to partially purify a 105-kDa protein(s)
Tyrosine Phosphorylation of ␣-Actininfrom PMA-activated outdated platelets. The activated platelets were lysed in a buffer containing 0.02% Triton X-100. Soluble proteins were precipitated with 10 -40% ammonium sulfate. After re-solubilization, aliquots from each fraction containing an equal amount of protein (15 g/lane) were resolved by SDS-PAGE. Gels were analyzed by silver staining or Western blotting and probed with the phosphotyrosine-specific mAb 4G10 (Fig. 1C) . A tyrosine-phosphorylated protein band of 105 kDa was enriched in 30 and 40% ammonium sulfate precipitates. These fractions were pooled and applied to a DEAE-Sepharose ion exchange column. Proteins retained on the column were eluted with a step gradient of 0.2-1 M NaCl. Duplicate samples containing an equal protein amount were subjected to SDS-PAGE and analyzed by silver staining or Western blotting and probing with mAb 4G10 (Fig. 1D) . Proteins eluted off the DEAE column with 0.8 and 1 M NaCl were pooled and Western-blotted onto an Immobilon polyvinylidene difluoride membrane and visualized with India ink. The 105-kDa region was cut out and HPLC purified peptides derived from endoproteinase Lys-C digestion were microsequenced (28) . A 12-amino acid internal sequence, QLEINFNTLQTK, was identified. The sequence was identical to human ␣-actinin sequences aac1_human, aac2_human, and aac3_human deposited in the Swiss Protein Database. Based on these data, the blots shown in Fig. 1 , A, C, and D, were reprobed with a polyclonal antiserum to ␣-actinin. In all three cases (Fig. 1, B, C, and D) , the ␣-actinin antiserum reacted with a single protein band of 105-kDa that co-migrated with the 105-kDa tyrosine-phosphorylated protein identified with mAb 4G10. Lysates from activated platelets were Western-blotted onto nitrocelullose and dephosphrylated with a recombinant tyrosine phosphatase (PTPase) from Y. enterocolitica. Dephosphorylation of the proteins eliminated reactivity with mAb 4G10 but had no effect on the reactivity of the samples with the antiserum to ␣-actinin (Fig. 1E) . Collectively, these data suggested that ␣-actinin may be the 105-kDa tyrosine-phosphorylated protein detected in activated platelets.
␣-Actinin Purification from PMA-activated Platelets-To further demonstrate that ␣-actinin is tyrosine-phosphorylated in activated platelets, an ␣-actinin purification protocol was developed. Prior ␣-actinin purification protocols relied on the relatively low solubility of this cytoskeletal protein in buffers containing 1% Triton X-100. For example, Rosenberg et al. (33) reported that more than 90% of platelet ␣-actinin was recovered in the Triton-insoluble pellet fraction. To further investigate the cellular partitioning of ␣-actinin and pp105, platelets were activated with PMA for 0, 1, 5, 10, 15, and 20 min before lysis (Fig. 2) . At the indicated time points, the platelets were lysed by the addition of an equal volume of buffer containing 2% Triton X-100 as described by Fox et al. (22) . Lysates were spun for 4 min at 12,000 ϫ g, yielding the low speed pellet. The resulting supernatants were sedimented for 2.5 h at 100,000 ϫ g, resulting in a soluble and an insoluble high speed pellet for each time point. The low speed and high speed fractions contain, respectively, cytoskeleton-and membrane-cytoskeletonassociated proteins (22) . Proteins contained in each fraction were Western-blotted and analyzed with mAb 4G10 and the ␣-actinin antiserum (Fig. 2, A and B) . PMA stimulation triggered a time-dependent decrease in the amount of ␣-actinin recovered in the soluble (supernatant fractions) and the membrane-cytoskeleton (high speed pellet) pools with a simultaneous increase in ␣-actinin localized to the cytoskeleton fraction (low speed pellet). Whereas in resting platelets 18% of ␣-actinin was recovered in the cytoskeleton fraction, 56% of ␣-actinin was recovered in the cytoskeleton fraction of platelets stimulated with PMA for 20 min (Fig. 2C) . In contrast, the fraction of soluble ␣-actinin dropped from 53 to 38%. Most dramatic, how- (A and B, lane 2) . Platelet lysates containing equal protein amounts were Western-blotted and probed with the anti-phosphotyrosine mAb 4G10 (A) or an ␣-actinin antiserum (B). The brackets mark the section in A that is shown in B. In C, outdated platelets were isolated and activated with 10 nM PMA. Platelets were lysed, and soluble proteins were precipitated with 10, 20, 30, and 40% ammonium sulfate (A.S.). Precipitated proteins were re-solubilized, and duplicate samples were analyzed by SDS-PAGE and silver staining or Western blots. In D, proteins re-solubilized after precipitation with 30 and 40% ammonium sulfate were applied to a DEAE-Sepharose column. Proteins retained on the column were eluted with a step gradient of 0.2-1 M NaCl. Duplicate samples containing equal protein amounts were analyzed by SDS-PAGE and silver staining or a Western blot and by probing with mAb 4G10 and ␣-actinin antiserum. The immunoblots shown in C and D correspond to the area of the respective silver-stained gel that is marked by the box. In E, fibrinogen-adherent platelet lysates were Western blotted onto nitrocellulose. The membrane was cut into strips that were subsequently incubated for 0 or 1 h in phosphatase buffer in the absence (CONTROL) or presence of 25 milliunits/ml of a recombinant 34-kDa fragment of the protein tyrosine phosphatase (PTPase) from Y. enterocolitica. The strips were probed with mAb 4G10 or ␣-actinin antiserum. The arrows indicate the position of pp105.
ever, was the change in ␣-actinin partitioning to the high speed/membrane-cytoskeleton fraction, which dropped from 29 to 4% over the same time period. Many other platelet proteins have been shown to move from the soluble to the cytoskeleton fraction of activated platelets (22, 34) . In contrast with this trend, a time-dependent increase in the tyrosine-phosphorylated 105-kDa protein and its predominant enrichment in the detergent-soluble fractions was observed. After a much longer exposure of the gel shown in Fig. 2A , we did note that ␣-actinin localized to the membrane-cytoskeleton compartment at the 20-min time point was also tyrosine-phosphorylated. However, no tyrosine phosphorylation signal associated with ␣-actinin in the cytoskeleton compartment was detected. Similar result were obtained with thrombin-stimulated platelets (22) . These data suggested that most of the phosphorylated 105-kDa protein was concentrated in fractions that contained soluble ␣-actinin.
To enrich for the soluble ␣-actinin pool, PMA-activated platelets were lysed by sonication. Soluble proteins were fractionated by gel filtration on a Sephacryl 300-HR column. Fractions containing ␣-actinin and tyrosine-phosphorylated proteins were identified, respectively, by Western blot analysis and probing with the antiserum to ␣-actinin and mAb 4G10. ␣-Actinin was resolved along with most other tyrosine-phosphorylated proteins (Fig. 3, A and B) . These data suggested that in activated platelets many proteins are included in high molecular weight complexes. To disrupt protein-protein interactions, ␣-actinin-containing fractions were combined and mixed with KCl to a final concentration of 0.6 M. Others (35) have shown that ␣-actinin interaction with actin is disrupted in the presence of KCl. The resulting solution was dialyzed, concentrated, and subjected to a high spin centrifugation. The supernatant sample was chromatographed on a Sephacryl 300-HR column pre-equilibrated with 0.6 M KCl containing buffer. As shown in Fig. 3 , C and D, several ␣-actinin-containing fractions were identified. The distribution of the 105-kDa tyrosine-phosphorylated protein among the various chromatographic fractions perfectly overlapped the distribution of ␣-actinin. ␣-Actinincontaining fractions were combined once again and passed through a CM-Sepharose column. ␣-Actinin and the 105-kDa tyrosine-phosphorylated protein were not retained on the CMSepharose column. ␣-Actinin-containing fractions were next loaded onto a DEAE-Sepharose column. Proteins were eluted off the column with a linear gradient of 0 -0.5 M NaCl. ␣-Actinin and the 105-kDa tyrosine-phosphorylated protein eluted once again in the same fractions (Fig. 3E) . The elution profile of ␣-actinin off of the DEAE column shown in Fig. 3E contrasted with the data shown in Fig. 1D . Based on the data shown in Fig. 3 , B and D, we hypothesize that ␣-actinin resolved in Fig.  1 is part of a complex that exhibits a high affinity for DEAE, whereas ␣-actinin that is separated from the complex exhibits a lower affinity for the DEAE matrix.
In the course of this purification, the tyrosine-phosphorylated protein migrating at 105 kDa was resolved only in fractions that contained ␣-actinin. Shown in Fig. 3G are a silverstained gel and a Western blot of pooled ␣-actinin-containing fractions recovered from the purification steps outlined in Fig.  3F . The co-purification of ␣-actinin and the 105-kDa protein through four different chromatographic separation conditions further demonstrated that ␣-actinin is tyrosine-phosphorylated in activated platelets.
Purified ␣-actinin was Western-blotted and analyzed with three distinct phosphotyrosine-specific antibodies, mAb 4G10, PY-20, and PY-99. All three antibodies reacted with the purified ␣-actinin protein yielding indistinguishable results (data not shown). Numerous attempts to immunoprecipitate the tyrosine-phosphorylated ␣-actinin from platelets lysed in various buffers have been unsuccessful. Attempts to immunoprecipitate ␣-actinin using two distinct ␣-actinin antisera or an ␣-actinin mAb (mAb 75.2 from Sigma) were equally unsuccessful. In contrast, when the purified ␣-actinin protein was subjected to immunoprecipitation with mAb PY20 (Fig. 4) or 4G10 (not shown), a tyrosine-phosphorylated protein of 105 kDa was immunoprecipitated. The tyrosine-phosphorylated protein was recognized by the ␣-actinin antiserum (Fig. 4, lane 2) . The addition of 50 M phenyl phosphate to the reaction mix significantly reduced both the phosphotyrosine signal and the amount of immunoprecipitated ␣-actinin (Fig. 4, lane 3) . Furthermore, ␣-actinin that remained in solution following the immunoprecipitation with mAb PY 20 reacted very weakly with mAb 4G10 (Fig. 4, lane 5) . Quantitative analysis of these data indicated that about 30 -40% of the total purified ␣-actinin protein was immunoprecipitated by mAb PY-20. As we sought to purify the soluble ␣-actinin pool, which, based on data shown in Fig. 2 , represents about 40% of the total ␣-acti- At the indicated time points, platelets were lysed in buffer containing 1% Triton X-100. Insoluble proteins were recovered by centrifugation for 4 min at 12,000 ϫ g (low speed pellet). Soluble proteins were spun for 2.5 h at 100,000 ϫ g yielding the high speed pellet and supernatant fractions. An aliquot from each fraction was subjected to SDS-PAGE and Western blotting. The blots were probed with mAb 4G10 (A) and ␣-actinin antiserum (B). The blot probed with the ␣-actinin antiserum was subjected to densitometric scanning (C). The percent of ␣-actinin recovered in each fraction was calculated relative to the total ␣-actinin recovered in the combined three fractions . FIG. 3 . ␣-Actinin purification from PMA-stimulated platelets. Purified outdated platelets were activated with PMA and lysed by sonication. Soluble proteins were subjected to gel filtration on a Sephacryl 300-HR column (A and B) . Panel A shows the chromatography profile of this column, and arrows point to the first and last fractions that were subsequently combined (fractions 3-12). Fractions containing ␣-actinin nin population, the ␣-actinin fraction that is tyrosine-phosphorylated may not exceed 12-15%.
Two-dimensional Analysis of ␣-Actinin-To further prove the identity of pp105 as ␣-actinin, platelet lysates were subjected to two-dimensional gel electrophoresis. Fibrinogen-adherent platelets (Fig. 5A) or PMA-stimulated platelets (data not shown) were lysed in 2% SDS, and duplicate samples containing 50 g of protein were run on parallel gels and examined by silver staining or Western blotting with mAb 4G10 and the antiserum to ␣-actinin (Fig. 5B) . The 105-kDa protein recog-
FIG. 3-continued
and tyrosine-phosphorylated proteins were identified, respectively, by Western blots and probing with mAb 4G10 and ␣-actinin antiserum (B). Most of the tyrosine-phosphorylated proteins, including the 105-kDa protein, were recovered in the ␣-actinin-containing fractions. The combined fractions were brought to 0.6 M KCl. The resulting sample was treated as described under "Materials and Methods." The sample was next resolved by gel filtration on a Sephacryl 300-HR column in the presence of 0.6 M KCl. C shows the chromatography profile of the column. Arrows point to the first and last fractions that were subsequently combined (fractions 4 -6). The migration profile of ␣-actinin and the tyrosine-phosphorylated proteins were determined by Western blots (D). The combined fractions were next applied to a CM-Sepharose column. ␣-Actinin was not retained on this column (data not shown). The sample was next loaded onto a DEAE-Sepharose column. ␣-Actinin was eluted off the column with a linear gradient of 0 -0.5M NaCl (E). Fractions containing ␣-actinin and tyrosine-phosphorylated proteins were identified by Western blots as described above. An outline of the purification scheme, including the protein amount recovered at each step, is shown in F. G, duplicate samples from the various purification steps marked in F were loaded onto two gels. One gel was silver-stained. The second gel was Western-blotted and probed with mAb 4G10 and ␣-actinin antiserum. Lanes 2-7 were loaded with 10 g of protein, and lanes 8 and 9 were loaded with 5 g of protein.
nized by the ␣-actinin antiserum exhibited a wide pI range. The reactivity of the ␣-actinin antiserum and mAb 4G10 matched perfectly. A similar broad pI range of platelet ␣-actinin has been observed by other investigators (36, 37) . ␣-Actinin was the only 105-kDa tyrosine-phosphorylated protein resolved by this method of analysis of total platelet lysates.
We have previously shown that treatment of platelets with bisindolylmaleimide, a protein kinase C inhibitor (29) , prevents platelet spreading on fibrinogen and tyrosine phosphorylation of the proteins of 101-105 kDa while having no effect on the induction of tyrosine phosphorylation of many other proteins (21) . We therefore reasoned that when compared with untreated platelet lysates, two-dimensional gel analysis of bisindolylmaleimide-pretreated platelet lysates should reveal significantly less reactivity with mAb 4G10 in the region recognized by the ␣-actinin antiserum. The results obtained, shown in Fig. 5 , fully confirmed our expectations. Pretreatment of the platelets with bisindolylmaleimide diminished the reactivity of mAb 4G10 with ␣-actinin, whereas its reactivity with many other proteins resolved on the two-dimensional gel remained unaltered. These data further demonstrated that ␣-actinin is tyrosine-phosphorylated in activated platelets. We have also noted that the overall electrophoretic mobility of ␣-actinin was unaffected by treatment of the platelets with bisindolylmaleimide, suggesting that the wide pI range of ␣-actinin on two-dimensional gels is affected by post-translational modifications other than its phosphorylation on tyrosine residues.
To determine the correlation between the two-dimensional electrophoretic mobility of ␣-actinin and platelet activation and to precisely determine the pI of ␣-actinin, unstimulated platelets and fibrinogen-adherent platelets were lysed in urea containing buffer and analyzed first by isoelectric focusing onto pre-cast polyacrylamide gels that contain an immobilized pH gradient followed by SDS-PAGE. Consistent with the computed theoretical pI for ␣-actinin, ␣-actinin from unstimulated platelet lysates migrated with a pI of about 5.2 (Fig. 5D) . The antibody to phosphotyrosine did not react with the latter ␣-actinin spot (data not shown). Platelet adhesion and spreading on fibrinogen (Fig. 5E ) or PMA stimulation (not shown) triggered a change in the electrophoretic mobility of ␣-actinin from the pI of 5.2 to a broad pI of about 4.9 -5.8. These data indicated that the broad pI migration pattern of ␣-actinin is platelet activationdependent. Consistent with the data obtained using unactivated platelet lysates, ␣-actinin from NIH 3T3 cells has a pI of about 5.2 and was shown to migrate within a very narrow pI range of 0.2-0.3 units (38) . To the best of our knowledge, the broad pI of ␣-actinin in activated platelets has not been observed in other cell systems and thus may be unique to platelets. C, bottom) . In D and E, unstimulated (D) and fibrinogenadherent platelets (E) were lysed in urea-containing buffer. Aliquots containing 100 g of protein were loaded onto pre-cast polyacrylamide gels containing an immobilized pH gradient of 3-10. The second dimension was carried on by SDS-PAGE. The gels were Western-blotted and probed with ␣-actinin antiserum (D and E (top)) and mAb 4G10 (E, bottom). mAb 4G10 did not react with the ␣-actinin spot shown in D (not shown).
DISCUSSION
Platelet activation by agonists and/or immobilized matrix proteins triggers tyrosine phosphorylation of multiple cellular proteins. In platelets that are activated by soluble agonists, tyrosine phosphorylation of a subset of proteins that includes pp125 FAK and two proteins of 101 and 105 kDa (pp101 and pp105) is dependent on ␣ IIb ␤ 3 integrin interaction with an adhesive ligand (19) . Tyrosine phosphorylation of pp125 FAK , pp101, and pp105 is also detected in platelets adherent to immobilized fibrinogen, an ␣ IIb ␤ 3 integrin ligand (9) . The sequence of an internal peptide derived from a partially purified tyrosine-phosphorylated protein of 105 kDa perfectly matched an internal 12-mer of ␣-actinin. Three lines of evidence extended this possibility. First, ␣-actinin and pp105 co-purified through four different chromatographic separation conditions. Furthermore, throughout this purification, the 105-kDa tyrosine-phosphorylated protein was only resolved in fractions that contained ␣-actinin. Second, purified ␣-actinin was immunoprecipitated by anti-phosphotyrosine antibodies. Third, ␣-actinin resolved by two-dimensional gel analysis of activated platelet lysates reacted with the antibodies to phosphotyrosine; the antibodies' reactivity with ␣-actinin was inhibited by pretreatment of platelets with bisindolylmaleimide, a protein kinase C inhibitor that prevents pp105 tyrosine phosphorylation. Based on these lines of evidence, we conclude that a fraction of ␣-actinin is tyrosine-phosphorylated in activated platelets. The tyrosine-phosphorylated ␣-actinin was recovered in the soluble fraction of PMA-stimulated platelets. This fraction contained less than 40% of the total ␣-actinin. Assuming that not all of ␣-actinin in the soluble fraction is tyrosine-phosphorylated, we estimate that less than 15-20% of the total ␣-actinin pool is tyrosine-phosphorylated in activated platelets.
␣-Actinin is a rod-shaped protein that forms an anti-parallel homodimer. It belongs to a large family of proteins that includes fimbrin, dystrophin, and spectrin (39) . All family members share a common 27-kDa F-actinin binding domain (40) . At least four human ␣-actinin genes have been described. One gene (aac1_ human) gives rise to two alternative spliced isoforms, the smooth muscle and the cytoskeletal/non-muscle isoforms (41) (42) (43) . The two isoforms differ in a region that spans the tail of the first EF-hand calcium binding motif; 27 amino acid residues in the non-muscle isoform were replaced by a distinct stretch of 22 amino acids in the smooth muscle isoform (43) . As a result of this substitution, the binding of the nonmuscle isoform to actin is inhibited by calcium, whereas actin interaction with the smooth muscle isoform is calcium-insensitive. Two genes (aac2_ and aac3_) encode several ␣-actinin skeletal muscle isoforms (44) . An additional human ␣-actinin isoform (aac4_) that exhibits 80% sequence identity to the smooth muscle and non-muscle isoforms was recently cloned from a tumor cell line (45) .
Rosenberg et al. (33) reported that the platelet ␣-actinin is a 105-kDa protein and that its binding to actin is calcium-sensitive. Although the platelet ␣-actinin has not been fully characterized or cloned, peptide maps suggested that platelet ␣-actinin is related to the non-muscle isoform. Consistent with published data (46) , the predicted pI of the non-muscle ␣-actinin isoform is 5.2. As shown in this study, a similar pI was resolved for ␣-actinin extracted from unstimulated platelets. In contrast, ␣-actinin extracted from activated platelets (shown here and in Ref. 37) or from platelets isolated from units of platelet concentrates (36) displayed a very broad pI. Since a similar modification was not reported in other cell types, it is possible that this post-translational modification(s) is unique to platelets. The nature of the modification(s) that alters the pI of platelet ␣-actinin remains to be determined.
The smooth and non-muscle ␣-actinin isoforms are localized along stress fibers, in focal adhesion plaques, and in adherence junctions (43, (47) (48) (49) . Otey and co-workers (50, 51) found that ␣-actinin interacts with synthetic peptides that correspond to the cytoplasmic tail of ␤ 1 and ␤ 3 integrins. ␣-Actinin interaction with the cytoplasmic tail of ␤ 2 integrins was also recently reported (52) . These data raised the possibility that in fibrinogen adherent and/or aggregated platelets, ␣-actinin may directly bind to the integrin receptor ␣ IIb ␤ 3 . Integrin receptor aggregates accumulate tensin and pp125 FAK , whereas the colocalization of ␣-actinin, talin, and vinculin with nascent adhesion plaques is dependent on integrin-ligand interaction (53, 54) . Studies with cytoplasmic integrin mutants showed that ␣-actinin interaction with integrin is not sufficient to trigger F-actin co-localization or focal adhesion plaques formation (54) . The accumulation of ␣-actinin in the plaque may, however, promote the formation of large protein complexes necessary for further plaque-stabilization. The data presented here are consistent with this notion and suggest that ␣-actinin extracted from activated platelet lysates elutes complexed with other proteins following separation on a molecular seizing column. The purification data, as well as cellular fractionation data, suggested that these complexes are largely soluble, raising the possibility that, in addition to its role as an actin cross-linking protein, ␣-actinin may complement the activity of pp125 FAK and serve as a scaffold to promote protein-protein interactions (55) . The reported interactions of ␣-actinin with actin, integrins, vinculin (56) , zyxin (57), the p85 subunit of PI3-kinase (58) , and PKN, a fatty acid and Rho-activated serine/threonine protein kinase (27) , are consistent with this possibility.
An integrin-mediated ␣-actinin tyrosine phosphorylation has not been reported prior to this study. Sefton and co-workers (59) noted that trace amounts of phosphotyrosine were incorporated in ␣-actinin isolated from Rous sarcoma-transformed chicken embryo fibroblasts, suggesting that ␣-actinin is not a preferred substrate of pp60 src . More recently, Egerton et al. (26) reported that ␣-actinin is tyrosine-phosphorylated in murine T cells activated by T cell antigen receptor ligation. These data suggested that ␣-actinin tyrosine phosphorylation may also occur in cells other than platelets. A PKN-mediated phosphorylation of purified ␣-actinin was also recently reported (27) . Time course studies with agonist-stimulated platelets revealed that the peak of tyrosine phosphorylation of multiple proteins, including that of pp105, is followed by their rapid dephosphorylation (34) . The dephosphorylation event was effectively blocked by calpeptin, an inhibitor of the protease calpain (34) and protein tyrosine phosphatases (60) . Calpeptin also abrogated platelet retraction of a fibrin clot, underscoring the significance of the balance between protein phosphorylation and dephosphorylation (34) . These data raise that possibility that the phosphorylation and dephosphorylation of pp105/␣-actinin may contribute to distinct, yet complementary, cellular events in the course of platelet activation and clot formation. pp125 FAK and pp105/␣-actinin tyrosine phosphorylation in platelets are closely regulated events (9, 19) . The induction of ␣-actinin and pp125
FAK tyrosine phosphorylation in PMAactivated platelets coincides with the formation of large platelet aggregates. In platelets adherent to fibrinogen, ␣-actinin and pp125 FAK tyrosine phosphorylation are not seen unless the platelets are fully spread. These observations suggest that ␣-actinin and pp125 FAK tyrosine phosphorylation in platelets are dependent on, rather than regulate, the massive cytoskeleton reorganization that takes place in activated platelets.
␣-Actinin and pp125 FAK tyrosine phosphorylation are dependent on protein kinase C activation (9, 19) . PI3-kinase inhibitors also abrogate pp125 FAK and pp105/␣-actinin phosphorylation in platelets adherent to fibrinogen (23) . It is possible that ␣-actinin is a pp125 FAK substrate. Alternatively, another kinase that is dependent on pp125 FAK phosphorylation for its localization to the plaque may phosphorylate ␣-actinin. The kinase that phosphorylates ␣-actinin, the sites of phosphorylation, and foremost, the role of ␣-actinin tyrosine phosphorylation in platelets are under investigation.
